Safety and efficacy of the combination of hyperbaric oxygen and 177Lu-DOTA-IBA in treating metastatic bone pain due to tumors
- 1Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University
- 2Hyperbaric Oxygen Therapy Room, Affiliated Hospital of Southwest Medical University
Abstract
The efficacy of the combination of hyperbaric oxygen therapy and the radionuclide treatment in targeting and treating metastatic bone pain due to tumors was analyzed in this study. Thirty-nine patients with metastatic bone tumors were divided into 2 groups. Group A consisted of patients receiving hyperbaric oxygen therapy combined with radionuclide therapy, and group B had patients receiving radionuclide therapy alone. Pain scores, sleep scores before and after treatment and the proportion of patients whose analgesic dosage was reduced within 24 h in both groups were analyzed at different time points before and after drug administration, and the scores between the groups were compared. All patients received 1 session of radionuclide therapy, with patients in group A receiving in combination with 1 course of hyperbaric oxygen therapy. On the seventh day after treatment, patients in Group A exhibited significantly lower pain scores than those in Group B, particularly during the initial 48 h. On day 30 post-treatment, sleep scores decreased in both patient groups. After 7 days of treatment, the proportion of patients in Group A and Group B experiencing painkiller reduction at different time points 24 h was 72.2% and 42.9%, respectively. There were no significant differences in bone marrow suppression status and renal function measurements between the two groups of patients before and after treatment. Hyperbaric oxygen combined with radionuclide therapy is safe and provides faster relief of bone pain in patients with bone metastases. Hyperbaric oxygen therapy can enhance the therapeutic effect of radionuclide therapy, and this combination warrants further evaluation for potential use in a clinical setting.
Related
- Evaluation of the Efficacy and Safety of Combination Therapy of Vamha and Myrha in the Management of PMOS: An Open-Label, Randomized, Multicentre, Comparative, Prospective Clinical Study
- Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
- AGE-related efficacy and safety of darolutamide triplet therapy in metastatic hormone-sensitive prostate cancer: are we ready for routine clinical practice?
- Efficacy and safety of a cetuximab biosimilar compared with Erbitux in patients with RAS wild-type metastatic colorectal cancer
- The efficacy and safety of adalimumab in treating axial spondyloarthritis: a systematic review and meta-analysis
BibTeX
@article{wang2026safety,
title = {{Safety and efficacy of the combination of hyperbaric oxygen and 177Lu-DOTA-IBA in treating metastatic bone pain due to tumors}},
author = {Yingwei Wang and Ya Liu and Jian Yang and Dengsai Peng and Qingchu Hua and Chunfang Zhang and Ying Zhang and Wei Wang and Yue Chen},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-62346-0},
url = {https://doi.org/10.1038/s41598-026-62346-0},
note = {CC BY},
}
RIS
TY - JOUR
TI - Safety and efficacy of the combination of hyperbaric oxygen and 177Lu-DOTA-IBA in treating metastatic bone pain due to tumors
AU - Yingwei Wang
AU - Ya Liu
AU - Jian Yang
AU - Dengsai Peng
AU - Qingchu Hua
AU - Chunfang Zhang
AU - Ying Zhang
AU - Wei Wang
AU - Yue Chen
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-62346-0
UR - https://doi.org/10.1038/s41598-026-62346-0
AB - The efficacy of the combination of hyperbaric oxygen therapy and the radionuclide treatment in targeting and treating metastatic bone pain due to tumors was analyzed in this study. Thirty-nine patients with metastatic bone tumors were divided into 2 groups. Group A consisted of patients receiving hyperbaric oxygen therapy combined with radionuclide therapy, and group B had patients receiving radionuclide therapy alone. Pain scores, sleep scores before and after treatment and the proportion of patients whose analgesic dosage was reduced within 24 h in both groups were analyzed at different time points before and after drug administration, and the scores between the groups were compared. All patients received 1 session of radionuclide therapy, with patients in group A receiving in combination with 1 course of hyperbaric oxygen therapy. On the seventh day after treatment, patients in Group A exhibited significantly lower pain scores than those in Group B, particularly during the initial 48 h. On day 30 post-treatment, sleep scores decreased in both patient groups. After 7 days of treatment, the proportion of patients in Group A and Group B experiencing painkiller reduction at different time points 24 h was 72.2% and 42.9%, respectively. There were no significant differences in bone marrow suppression status and renal function measurements between the two groups of patients before and after treatment. Hyperbaric oxygen combined with radionuclide therapy is safe and provides faster relief of bone pain in patients with bone metastases. Hyperbaric oxygen therapy can enhance the therapeutic effect of radionuclide therapy, and this combination warrants further evaluation for potential use in a clinical setting.
SN - 2045-2322
ER -